How are Interactions Taken into Account in Studies on Conventional and Complementary Therapies for Breast Cancer Patients with Menopausal Complaints?

Wie werden Interaktionen in Studien zur konventionellen und komplementären Therapie bei menopausalen Beschwerden von Brustkrebspatientinnen berücksichtigt?

Authors

J. Hübner¹, K. Münstedt², R. Mücke³, O. Mücke⁴

Affiliations

¹ Dr. Senckenbergisches Chronomedizinisches Institut, Universität Frankfurt, Frankfurt

² Frauenklinik, Universitätsklinikum Gießen, Gießen

³ Strahlentherapie, Klinikum Lippe, Lippe

⁴ Strahlentherapie, Franziskus Hospital, Bielefeld

Key words

- breast cancer
- antihormone therapy
- hormone withdrawal signs
- complementary medicine
- interactions

Schlüsselwörter

- Mammakarzinom
- antihormonelle Therapie
- Hormonentzugserscheinungen
- Komplementärmedizin
- Interaktionen

received 15.6.2012

revised 4.9.2012

accepted 4.9.2012

Bibliography

DOI <http://dx.doi.org/10.1055/s-0032-1327854>
Geburtsh Frauenheilk 2012; 72: 933–939 © Georg Thieme Verlag KG Stuttgart · New York · ISSN 0016-5751

Correspondence

Dr. Jutta Hübner
Universität Frankfurt
Dr. Senckenbergisches
Chronomedizinisches Institut
Theodor-Stern-Kai 7
60590 Frankfurt
huebner@med.uni-frankfurt.de

Abstract

Introduction: Postmenopausal symptoms in breast cancer patients undergoing antihormone treatment lead to high drop-out rates from the therapy. From the therapeutic point of view, methods of both conventional and complementary medicine are concerned. Interactions are being discussed in cases of natural substances. However, they are also relevant for conventional medical substances. The aim of this analysis is to answer the question as to what extent potential interactions are taken into account in clinical studies and reviews on supportive therapies.

Materials and Methods: Clinical studies and reviews were identified by means of a systematic search and analysed with regard to the consideration of potential interactions.

Results: Altogether 46 clinical studies and one Cochrane review were found. Among the 35 studies on conventional drug therapies, 5 (14%) took possible interactions into account. Among the 17 studies on complementary medicine, there were 2 (11.7%) such publications. The Cochrane review did not mention interactions.

Discussion: For future studies in which interactions cannot be excluded, a strategy to control for their clinically relevant consequences should be developed. The present authors suggest that the use of survival and recurrence data as secondary endpoints, also for studies on purely supportive therapies, is a reasonable approach. The resulting considerations for study routines are listed thematically.

Zusammenfassung

Einleitung: Postmenopausale Symptome bei Mammakarzinompatientinnen unter antihormoneller Therapie führen zu einer hohen Abbrecher-rate der Therapie. Therapeutisch kommen Methoden der konventionellen wie der komplementären Medizin infrage. Bei den natürlichen Substanzen werden Interaktionen diskutiert. Sie betreffen aber auch Substanzen der konventionellen Medizin. Ziel der Analyse ist die Frage, inwieweit in klinischen Studien und Reviews zur supportiven Therapie potentielle Interaktionen berücksichtigt werden.

Material und Methodik: Mittels systematischer Recherche wurden klinische Studien und Reviews identifiziert und im Hinblick auf die Berücksichtigung möglicher Interaktionen analysiert.

Ergebnisse: Es wurden 46 klinische Studien und ein Cochrane-Review erfasst. Von den 35 Studien zur konventionellen medikamentösen Therapie berücksichtigten 5 (14%) evtl. Interaktionen. Von 17 Studien zur Komplementärmedizin waren es 2 Arbeiten (11,7%). Das Cochrane-Review geht nicht auf Interaktionen ein.

Diskussion: Für zukünftige Studien sollte bei nicht auszuschließender Interaktion eine Strategie zur Kontrolle der klinisch relevanten Folgen erarbeitet werden. Die Autoren schlagen hierfür Überlebens- und Rezidivdaten als sekundäre Endpunkte auch bei rein supportiven Therapiestudien als sinnvollen Ansatz vor. Die sich hieraus ergebenden Überlegungen für den Studienalltag werden im Artikel thematisiert.

Introduction

Menopausal complaints are a frequent phenomenon in patients with breast cancer. They are triggered or, respectively, intensified not only in the course of primary or adjuvant chemo- or antihor-

mone therapy for younger women but also by antihormone therapy for postmenopausal women. According to literature data about 40–50% of all breast cancer patients suffer from postmenopausal symptoms.

The most disturbing symptoms thereby are hot flushes, mood fluctuations and fatigue. This leads in a not negligible number of patients to poor compliance or even to termination of the therapy. For antihormone therapy statistics show that up to 50% of the patients do not hold to the recommended therapy duration of 5 years, whereby the grey zone is assumed to be very large [1–4].

Unfortunately it is also possible that this has a negative effect on the prognosis for the patients.

Accordingly, informing the patients about the possibilities of the respective supportive therapies and their practical application is of particular significance for the therapeutic success. In such situations, the patients may also express the wish for a “natural” therapy. In the past years the attention of oncologists has been directed towards the interaction potential of, above all, phytotherapeutic agents [5]. Well known and commonly used substances are St. John’s wort or grapefruit juice. Interactions between drugs or also with nutritional supplements may be based on their different mechanisms of action. Best known are the influences on pharmacokinetics exerted by the action of cytochrome P 450 enzymes (especially CYP 450 3A4, but also Pgp and in gynaecological oncology 2D6). These interactions have an impact not only on the first-pass metabolism but also on the formation of active metabolites. The effects can vary widely from patient to patient and depend, among others, on the individual enzyme constellations as well as on other confounding factors such as additional co-medications, nutrition, etc. Further interactions are possible via the direct action on the same target structures in the cell (receptors, molecules in the signalling chains), as well as in the surroundings of the receptors. The bioavailability of drugs can result from influences on transport molecules as well as direct chemical interactions. The latter mechanism is well known for pH shifts in the gastrointestinal tract or for the direct chemical interaction of two molecules such as, e.g., bortezomib and catechins from green tea [6, 7].

However, potential interactions are, of course, not limited to complementary medicine, but also are involved in the substances of conventional medicine.

Every 4th tumour patient is endangered by interactions between chemotherapy, supportive therapy and/or drugs for co-morbidities [8].

Accordingly in studies on new drugs, increasingly comprehensive lists of drugs and natural substances that should not be consumed during the study period are being compiled. Known pre-clinical and clinical, especially pharmacological, data on interactions provide the basis for the exclusion of drugs.

For patients undergoing adjuvant antihormone therapy the question of interactions is of particular importance as this is a curative situation and, simultaneously, a possible negative influence may only be detected later when, probably, a connection with drug causing the interaction can no longer be demonstrated. At the same time the occurrence of metastases means an incurable and ultimately fatal situation for a great majority of the patients.

Thus, the target of a supportive therapy in breast cancer is to avoid the hormone withdrawal symptoms induced directly by the antihormone therapy without reducing the antihormone action on the tumour cells. Especially in cases of receptor-positive tumours, care must be taken that the supportive therapy does not lead to an improvement of the menopausal symptoms by directly or indirectly triggering a hormone or hormone-like activity.

The aim of the authors is to analyse to what extent in the past years clinical studies on supportive therapy for menopausal symptoms that have been induced by an adjuvant therapy for breast cancer have taken the topic of potential interactions into account.

Material and Methods

From a Medline search (search day: 2012-03-31), we extracted all articles on clinical studies or reviews and meta-analyses on symptom control for menopausal complaints in patients with breast cancer.

Our search strategy is presented in Box 1. The search was limited to articles that were available as full texts. Besides Medline, the Cochrane library was used regarding reviews on supportive therapies for breast cancer. Articles on purely psycho-oncological procedures including behavioural therapy and physical activity as well as methods such as Tai Chi, Qigong and Yoga were excluded from the start, since therapeutic interactions probably do not play an essential role in these processes.

Search strategy and terms used to identify publications

MeSH terms search:

1. breast cancer

Direct keyword search:

1. hot flushes
2. vasomotor symptoms
3. menopausal symptoms
4. osteoporosis
5. tamoxifen
6. letrozol
7. anastrozol
8. exemestan
9. fulvestrant
10. ([2]or[3]or[4]or[5])
11. ([6]or[7]or[8]or[9]or[10])
12. ([11] AND [1])
13. ([11] AND [12])
14. ([13]or[14])

Limits: clinical study, review, meta-analysis;

language: English

On the basis of the title and abstract, we checked whether the article presented a controlled clinical study on supportive therapy for menopausal symptoms or, respectively, a corresponding review or meta-analysis. Subsequently the article was analysed as to whether the topic of interactions was recognisably taken into consideration. Two criteria were applied for this:

1. Does the article contain an argumentation taking the topic into consideration? And has a possible interaction already been excluded with certainty during the study planning on the basis of unambiguous published data?
2. When an interaction cannot be excluded with certainty: was the measurement of parameters that were suitable to answer questions about interactions (survival data: disease-free survival and overall survival) planned and documented?
3. When 1 or 2 was not fulfilled: were considerations on possible interactions included in the discussion?

Fig. 1 Due to the fact that in some studies different substances were being compared in two active study arms, the total of studies exceeds 46.

4. In addition, we checked whether the documented side effects were suggestive of possible interactions.

Results

Altogether between 1994 and 2010, 45 clinical studies (references [9–56]) on menopausal complaints in patients with breast cancer and one Cochrane review were published. Except for 4, all were published in journals that can be assigned to the field of conventional medicine. Articles on complementary therapeutic procedures such as phytopharmaceuticals, vitamin E and acupuncture also appeared in part in oncological journals with high impact factors (Journal of Clinical Oncology, Annals of Oncology). A survey on the topics and number of articles in which a specific substance was tested is given in [Table 1](#) and [Fig. 1](#).

Altogether conventional drug therapies were tested 35 times in controlled studies. In 5 articles (14%) the possibility of an interaction and thus a negative effect on the antihormone therapy was discussed (2 studies on tibolone, 1 each on gabapentin, paroxetine and megestrol acetate). These articles dated from the years 1994, 2000, 2 from 2005, and 2009.

Methods of complementary therapy were tested 17 times. Of these 2 articles (11.7%) from the years 2001 and 2003 discussed the possibility of interactions (both studies on Cimicifuga).

Of these 35 studies, only 4 (9% of all publications) have collected data that allow the assumption of clinically relevant interactions. These are two studies on tibolone (survival; activity on the endometrium) and the 2 studies on Cimicifuga (recurrence control every 2 months; measurements of FSH and LH).

Besides possible interactions, the question of side effects is also important with regard to therapeutic safety. Of the 35 studies on conventional therapy, side effects were reported in 32 studies. Of the 16 studies on complementary therapy, 8 mentioned side effects. Among the articles on conventional therapy, type, extent and frequency of the side effects were given in comparison to a

control group whereas the studies on complementary therapy were usually limited to comments on the generally good tolerability.

The Cochrane review by Rada et al. [47] collected all non-hormonal interventions together. Data on vitamin E, clonidine, ergotamine, phenobarbital, Belladonna, gabapentin, SSRIs and SNRIs (venlafaxine, paroxetine, sertraline, fluoxetine, mirtazapin, trazodone) as well as non-drug therapies such as meditation, Ayurveda, aroma therapy, acupuncture, magnetic therapy, relaxation procedures, biofeedback, hypnosis, behavioural therapies including respiration therapy and sports. Explicitly excluded were herbal oestrogens (isoflavones from soy and red clover), Cimicifuga and tibolone on the basis of their oestrogen-like mechanisms. The Cochrane review does not deal with interactions between antihormone therapy and the various pharmacological procedures. Also the question of a possible impact on disease course, progress and survival was not discussed.

Discussion

Altogether, the topic of interactions was taken into consideration in merely 7 of the 45 articles, and there was no difference in frequency between articles on conventional and complementary medicine.

It could be expected that the consideration of interactions would have increased after the interactions of St. John's wort became known. However this is not the case, either in conventional supportive therapy or in complementary medicine [8].

It cannot be assumed from this lack of consideration in the articles that the topic was indeed ignored by the authors, rather they may have made such considerations while planning the study and then dismissed the possibility of interactions for the chosen test substances.

The latter argumentation is, however, unlikely since conventional substances that are metabolised via CYP 450 3A4 or CYP 450 2D6

Table 1 Survey of studies on supportive therapy for menopausal complaints under endocrine therapy for patients with breast cancer.

Author	Publication year	Study name	Location	Summary of contents
Barton	1998	Prospective evaluation of vitamin E for hot flashes in breast cancer survivors.	Rochester	Vitamin E vs. placebo; significant difference without clinical relevance; patients did not prefer verum
Barton	2002	Depomedroxyprogesterone acetate for hot flashes.	Rochester	Medroxyprogesterone i. m. pre-post comparison effective
Bertelli	2002	Intramuscular depot medroxyprogesterone versus oral megestrol for the control of postmenopausal hot flashes in breast cancer patients: a randomized study.	Cuneo, Italy	Medroxyprogesterone i. m. vs. megestrol p. o.; no difference under the therapy, longer effect of i. m. therapy
Biglia	2005	Evaluation of low-dose venlafaxine hydrochloride for the therapy of hot flushes in breast cancer survivors.	Turin	Venlafaxine; open study; significant improvement in pre-post comparison
Biglia	2009	Non-hormonal treatment of hot flushes in breast cancer survivors: gabapentin vs. vitamin E.	Turin	Vitamin E vs. gabapentin; improvement with gabapentin; vitamin E without effect
Bordeleau	2010	Multicenter, randomized, cross-over clinical trial of venlafaxine versus gabapentin for the management of hot flashes in breast cancer survivors.	Ontario	Comparison of venlafaxine and gabapentin; patients preferred venlafaxine
Buijs	2009	Venlafaxine versus clonidine for the treatment of hot flashes in breast cancer patients: a double-blind, randomized cross-over study.	Groningen	Venlafaxine vs. clonidine; both moderately active; venlafaxine had more side effects
Carpenter	2007	Evaluating the role of serotonin in hot flashes after breast cancer using acute tryptophan depletion.	Indianapolis	Effect of tryptophan depletion on menopausal symptoms: no deterioration
Clover	2002	Homeopathic treatment of hot flushes: a pilot study.	Tunbridge Wells	Homeopathy effective in case series
Deng	2007	Randomized, controlled trial of acupuncture for the treatment of hot flashes in breast cancer patients.	New York	Acupuncture vs. sham-acupuncture; no significant difference
Dyer	2008	A study to look at the effects of a hydrolat spray on hot flushes in women being treated for breast cancer.	London	Spray with peppermint and neroli vs. spray with water; peppermint spray marginally better
Elkins	2008	Randomized trial of a hypnosis intervention for treatment of hot flashes among breast cancer survivors.	Waco, USA	Hypnosis vs. no therapy; hypnosis lead to a significant improvement of symptoms
Frisk	2008	Long-term follow-up of acupuncture and hormone therapy on hot flushes in women with breast cancer: a prospective, randomized, controlled multicenter trial.	Linköping, Sweden	Electro-acupuncture vs. hormone therapy; hormone therapy is more effective but electro-acupuncture is also effective
Golberg	1994	Transdermal clonidine for ameliorating tamoxifen-induced hot flashes.	Danville, USA	Clonidine vs. placebo; significant effect, clinical limited but with marked side effects
Goodwin	2008	Phase III randomized placebo-controlled trial of two doses of megestrol acetate as treatment for menopausal symptoms in women with breast cancer: Southwest Oncology Group Study 9626.	Springfield, USA	Comparison of 21 doses of megestrol acetate; both effective, 20 mg recommended for therapy
Hernandez	2003	Cimicifuga racemosa for the treatment of hot flushes in women surviving breast cancer.	Caracas, Venezuela	Cimicifuga vs. control group; significant improvement
Hervik	2009	Acupuncture for the treatment of hot flashes in breast cancer patients, a randomized, controlled trial.	Tonsberg, Norway	Acupuncture vs. sham-acupuncture; acupuncture led to larger effect than sham-acupuncture
Jacobs	2005	Homeopathy for menopausal symptoms in breast cancer survivors: a preliminary randomized controlled trial.	Seattle	Classical homeopathy vs. homeopathic complex agent vs. placebo; marginally better effect of classical, individual prescription
Jacobson	2001	Randomized trial of black cohosh for the treatment of hot flashes among women with a history of breast cancer.	New York	Cimicifuga vs. placebo; no significant difference
Joffe	2010	Augmentation of venlafaxine and selective serotonin reuptake inhibitors with zolpidem improves sleep and quality of life in breast cancer patients with hot flashes: a randomized, double-blind, placebo-controlled trial.	Boston	Comparison of SSRI/SNRI ± zolpidem; combination therapy superior with regard to sleeping
Kenemans	2009	Safety and efficacy of tibolone in breast-cancer patients with vasomotor symptoms: a double-blind, randomised, non-inferiority trial.	Amsterdam	Tibolone vs. placebo; tibolone improved the menopausal complaints, but also increased risk of recurrence
Kimmick	2006	Randomized, double-blind, placebo-controlled, crossover study of sertraline (Zoloft) for the treatment of hot flashes in women with early stage breast cancer taking tamoxifen.	Winston-Salem, USA	Sertraline vs. placebo; sertraline significantly better
Kroiss	2005	The effect of tibolone in postmenopausal women receiving tamoxifen after surgery for breast cancer: a randomised, double-blind, placebo-controlled trial.	Vienna	Tibolone vs. placebo; significant action, no effect on the endometrium (no data on recurrence rate)
Lipov	2008	Effects of stellate-ganglion block on hot flushes and night awakenings in survivors of breast cancer: a pilot study.	Hoffman Estates; USA	Stellate-ganglion blockade; blockade is an effective therapy
Loibl	2007	Venlafaxine is superior to clonidine as treatment of hot flashes in breast cancer patients – a double-blind, randomized study.	Frankfurt/Main	Venlafaxine vs. clonidine; venlafaxine significantly better

Table 1 Survey of studies on supportive therapy for menopausal complaints under endocrine therapy for patients with breast cancer. (continued)

Author	Publication year	Study name	Location	Summary of contents
Loprinzi	1994	Megestrol acetate for the prevention of hot flashes.	Rochester	Megestrol acetate vs. placebo; significant effect
Loprinzi	1998	Pilot evaluation of venlafaxine hydrochloride for the therapy of hot flashes in cancer survivors.	Rochester	Venlafaxine effective in pre-post comparison
Loprinzi	2000	Venlafaxine in management of hot flashes in survivors of breast cancer: a randomised controlled trial.	Rochester	Venlafaxine vs. placebo; significant improvement
Loprinzi	2002	Phase III evaluation of fluoxetine for treatment of hot flashes.	Rochester	Fluoxetine vs. placebo; fluoxetine significantly better
Mac Gregor	2005	A randomised double-blind controlled trial of oral soy supplements versus placebo for treatment of menopausal symptoms in patients with early breast cancer.	Glasgow	Soy supplement vs. placebo; no difference
Mariani	2005	Hot-flashes in breast cancer survivors: effectiveness of low-dosage fluoxetine. A pilot study.	Rome	Fluoxetine significantly effective in pre-post comparison
Nikander	2004	Effects of phytoestrogens on bone turnover in postmenopausal women with a history of breast cancer.	Helsinki	Isoflavones vs. placebo; endpoint: laboratory values for bone metabolism; marginally less turnover under isoflavones
Pandya	2000	Oral clonidine in postmenopausal patients with breast cancer experiencing tamoxifen-induced hot flashes: a University of Rochester Cancer Center Community.	New York	Clonidine vs. placebo; significant improvement
Pandya	2004	Pilot study using gabapentin for tamoxifen-induced hot flashes in women with breast cancer.	Rochester	Gabapentin significantly better in pre-post comparison
Pandya	2005	Gabapentin for hot flashes in 420 women with breast cancer: a randomised double-blind placebo-controlled trial.	Rochester	Gabapentin in 2 different doses vs. placebo; gabapentin 900 mg/d significantly better
Quella	1998	Evaluation of soy phytoestrogens for the treatment of hot flashes in breast cancer survivors: A North Central Cancer Treatment Group Trial.	Rochester	Soy isoflavones vs. placebo; no differences
Quella	2000	Long term use of megestrol acetate by cancer survivors for the treatment of hot flashes.	Rochester	Follow-up questioning of the patients of the 1998 study; some continued to use megestrol with success, no indications of side effects in long-term use
Stearns	2000	A pilot trial assessing the efficacy of paroxetine hydrochloride (Paxil) in controlling hot flashes in breast cancer survivors.	Washington	Paroxetine vs. placebo; significant effect
Stearns	2005	Paroxetine is an effective treatment for hot flashes: results from a prospective randomized clinical trial.	Washington	Paroxetine vs. placebo; paroxetine significantly better
Thompson	2005	A pilot, randomized, double-blinded, placebo-controlled trial of individualized homeopathy for symptoms of estrogen withdrawal in breast-cancer survivors.	Bristol	Homeopathic consultation + homeopathic drugs or placebo; no difference
Thompson	2008	Levetiracetam for the treatment of hot flashes: a phase II study.	Rochester	Levetiracetam significantly reduced menopausal symptoms
Van Patten	2002	Effect of soy phytoestrogens on hot flashes in postmenopausal women with breast cancer: a randomized, controlled clinical trial.	Vancouver	Isoflavone-rich soy drink vs. rice drink; marked improvement in both groups, no difference
Walker	2010	Acupuncture versus venlafaxine for the management of vasomotor symptoms in patients with hormone receptor-positive breast cancer: a randomized controlled trial.	Detroit	Acupuncture vs. venlafaxine; both arms comparable
Weitzner	2002	A pilot trial of paroxetine for the treatment of hot flashes and associated symptoms in women with breast cancer.	Tampa, USA	Paroxetine significantly effective in pre-post comparison
Wu	2010	The efficacy of sertraline for controlling hot flashes in women with or at high risk of developing breast cancer.	Houston	Sertraline vs. placebo; sertraline not superior

and thus possess a potential for interactions were tested in the studies. One such example is the studies on paroxetine with initially positive evidence of efficacy in regard to the primary endpoint and formulation of corresponding therapy recommendations. The question of safety first arose later and the corresponding recommendations were revised [57,58].

For all studies on supportive therapy, irrespective of whether they come from the field of complementary medicine or conventional therapy, a prior clarification of possible interactions should be undertaken. Neither for conventional nor for complementary medicine should a lack of side effects and interactions be proposed in the absence of an exact analysis.

For ethical reasons the performance of a study is only justifiable when

1. interactions can be excluded with certainty or, respectively
2. when this is not possible and/or also cannot be confirmed by further preclinical research, intensified precautionary measures should be undertaken for the participating patients.

In every case, suitable parameters such as survival and recurrence data should be required as secondary endpoints even for studies on purely supportive therapies, although this may need a longer follow-up period and thus longer time to achieve publishable results with higher study costs or, respectively, influence the approval of a new drug. For the case of highly unlikely interactions, a minimal requirement must be that a follow-up is undertaken and that as soon as data become available they are published and presented so that renewed scientific discussion

and control of the approval may take place. Here, if necessary, innovative models such as cooperation with clinical cancer registers should be considered.

In studies on new drugs, increasingly comprehensive lists of drugs and natural substances that should not be consumed during the study period are being compiled – although this facilitates the performance of the study, the later implementation in health-care reality becomes more difficult and, possibly, may even endanger the safety of the patient when these restrictions are not followed. Although the latter increases for the study participants in this process, the gaps in knowledge and the danger of later interactions outside of the study increase subsequently for patients treated in clinical routine outside of the studies. This restrictive procedure also strongly reduces the number of patients who may later be eligible for the therapy. The question is how can we avoid this dilemma? There is certainly doubt that confirmed interactions with clinical consequences must be excluded. On the other hand it is the clinical relevance that we must take into consideration – not every impact on an enzyme in the laboratory leads to clinical relevance. In these cases measurements of serum levels of the drug may provide useful hints. Unchanged levels, however, do not exclude other types of interaction (e.g., in the tumour cell). Thus, in cases of doubt only an analysis of survival parameters can lead to important deductions.

For the practicing physician it is important to have a good knowledge of the various therapeutic possibilities for hormone withdrawal symptoms in patients with breast cancer. It is also worthwhile to be aware of the good data concerning non-drug procedures such as physical activity, relaxation processes and cognitive movement exercises (Tai Chi, Qigong and Yoga).

Facit for Practitioners

▼
Hormone withdrawal symptoms are a frequent occurrence that leads to premature therapy termination by many breast cancer patients. Therapeutic substances of both conventional and complementary medicine are currently available. In both fields, drug interactions must be expected. This question is often not considered in clinical studies so that the prescribing physician must acquire additional information. A primary attempt with non-drug procedures such as physical activity, relaxation processes and cognitive movement exercises (Tai Chi, Qigong und Yoga) is a recommendable option for many patients.

Conflict of Interest

▼
None.

References

- 1 Hadji P *et al.* Onkologie. Non-Compliance in der adjuvanten, endokrinen Therapie des Mammakarzinoms. *Geburtsh Frauenheilk* 2007; 67: 497
- 2 Brucker S. Onkologie. Postmenopause: adjuvante endokrine Therapie des frühen hormonrezeptorpositiven Mammakarzinoms. *Geburtsh Frauenheilk* 2008; 68: 847
- 3 Distler W *et al.* Unerwünschte gynäkologische und operative Interventionen bei der Behandlung des postmenopausalen Mammakarzinoms mit Anastrozol und Tamoxifen. *Geburtsh Frauenheilk* 2010; 70: 57
- 4 Bossart M *et al.* Frühes Mammakarzinom – Lebensqualität nach Switch von Tamoxifen auf Exemestan. *Geburtsh Frauenheilk* 2011; 71: 847
- 5 Sparreboom A *et al.* Herbal interactions in the United States: potential adverse interactions with anticancer agents. *J Clin Oncol* 2003; 22: 2489–2503
- 6 <http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm080499.htm#background>; Stand: 30.8.2012
- 7 Zhang L *et al.* Drug interactions evaluation: an integrated part of risk assessment of therapeutics. *Toxicol Appl Pharmacol* 2010; 243: 134–145
- 8 Hu Z *et al.* St. John's wort modulates the toxicities and pharmacokinetics of CPT-11 (irinotecan) in rats. *Pharm Res* 2005; 22: 902–914
- 9 Barton D *et al.* Depomedroxyprogesterone acetate for hot flashes. *J Pain Symptom Manage* 2002; 24: 603–607
- 10 Barton DL *et al.* Prospective evaluation of vitamin E for hot flashes in breast cancer survivors. *J Clin Oncol* 1998; 16: 495–500
- 11 Bertelli G *et al.* Intramuscular depot medroxyprogesterone versus oral megestrol for the control of postmenopausal hot flashes in breast cancer patients: a randomized study. *Ann Oncol* 2002; 13: 883–888
- 12 Biglia N *et al.* Non-hormonal treatment of hot flushes in breast cancer survivors: gabapentin vs. vitamin E. *Climacteric* 2009; 12: 310–318
- 13 Biglia N *et al.* Evaluation of low-dose venlafaxine hydrochloride for the therapy of hot flushes in breast cancer survivors. *Maturitas* 2005; 52: 78–85
- 14 Bordeleau L *et al.* Multicenter, randomized, cross-over clinical trial of venlafaxine versus gabapentin for the management of hot flashes in breast cancer survivors. *J Clin Oncol* 2010; 28: 5147–5152
- 15 Buijs C *et al.* Venlafaxine versus clonidine for the treatment of hot flashes in breast cancer patients: a double-blind, randomized cross-over study. *Breast Cancer Res Treat* 2009; 115: 573–580
- 16 Carpenter JS *et al.* Randomized, double-blind, placebo-controlled crossover trials of venlafaxine for hot flashes after breast cancer. *Oncologist* 2007; 12: 124–135
- 17 Carpenter JS *et al.* Evaluating the role of serotonin in hot flashes after breast cancer using acute tryptophan depletion. *Menopause* 2009; 16: 644–652
- 18 Clover A *et al.* Homeopathic treatment of hot flushes: a pilot study. *Homeopathy* 2002; 91: 75–79
- 19 Deng G *et al.* Randomized, controlled trial of acupuncture for the treatment of hot flashes in breast cancer patients. *J Clin Oncol* 2007; 25: 5584–5590
- 20 Dyer J *et al.* A study to look at the effects of a hydrolat spray on hot flushes in women being treated for breast cancer. *Complement Ther Clin Pract* 2008; 14: 273–279
- 21 Elkins G *et al.* Randomized trial of a hypnosis intervention for treatment of hot flashes among breast cancer survivors. *J Clin Oncol* 2008; 26: 5022–5026
- 22 Frisk J *et al.* Long-term follow-up of acupuncture and hormone therapy on hot flushes in women with breast cancer: a prospective, randomized, controlled multicenter trial. *Climacteric* 2008; 11: 166–174
- 23 Goldberg RM *et al.* Transdermal clonidine for ameliorating tamoxifen-induced hot flashes. *J Clin Oncol* 1994; 12: 155–158
- 24 Goodwin JW *et al.* Phase III randomized placebo-controlled trial of two doses of megestrol acetate as treatment for menopausal symptoms in women with breast cancer: Southwest Oncology Group Study 9626. *J Clin Oncol* 2008; 26: 1650–1656
- 25 Hernandez MG *et al.* Cimicifuga racemosa for the treatment of hot flushes in women surviving breast cancer. *Maturitas* 2003; 44 (Suppl. 1): S59–S65
- 26 Hervik J *et al.* Acupuncture for the treatment of hot flashes in breast cancer patients, a randomized, controlled trial. *Breast Cancer Res Treat* 2009; 116: 311–316
- 27 Jacobs J *et al.* Homeopathy for menopausal symptoms in breast cancer survivors: a preliminary randomized controlled trial. *J Altern Complement Med* 2005; 11: 21–27
- 28 Jacobson JS *et al.* Randomized trial of black cohosh for the treatment of hot flashes among women with a history of breast cancer. *J Clin Oncol* 2001; 19: 2739–2745
- 29 Joffe H *et al.* Augmentation of venlafaxine and selective serotonin reuptake inhibitors with zolpidem improves sleep and quality of life in breast cancer patients with hot flashes: a randomized, double-blind, placebo-controlled trial. *Menopause* 2010; 17: 908–916
- 30 Kenemans P *et al.* Safety and efficacy of tibolone in breast-cancer patients with vasomotor symptoms: a double-blind, randomised, non-inferiority trial. *Lancet Oncol* 2009; 10: 135–146

- 31 Kimmick GG *et al.* Randomized, double-blind, placebo-controlled, crossover study of sertraline (Zoloft) for the treatment of hot flashes in women with early stage breast cancer taking tamoxifen. *Breast J* 2006; 12: 114–122
- 32 Kroiss R *et al.* The effect of tibolone in postmenopausal women receiving tamoxifen after surgery for breast cancer: a randomised, double-blind, placebo-controlled trial. *BJOG* 2005; 112: 228–233
- 33 Lipov EG *et al.* Effects of stellate-ganglion block on hot flushes and night awakenings in survivors of breast cancer: a pilot study. *Lancet Oncol* 2008; 9: 523–532
- 34 Loibl S *et al.* Venlafaxine is superior to clonidine as treatment of hot flashes in breast cancer patients – a double-blind, randomized study. *Ann Oncol* 2007; 18: 689–693
- 35 Loprinzi CL *et al.* Venlafaxine in management of hot flashes in survivors of breast cancer: a randomised controlled trial. *Lancet* 2000; 356: 2059–2063
- 36 Loprinzi CL *et al.* Megestrol acetate for the prevention of hot flashes. *N Engl J Med* 1994; 331: 347–352
- 37 Loprinzi CL *et al.* Pilot evaluation of venlafaxine hydrochloride for the therapy of hot flashes in cancer survivors. *J Clin Oncol* 1998; 16: 2377–2381
- 38 Loprinzi CL *et al.* Phase III evaluation of fluoxetine for treatment of hot flashes. *J Clin Oncol* 2002; 20: 1578–1583
- 39 MacGregor CA *et al.* A randomised double-blind controlled trial of oral soy supplements versus placebo for treatment of menopausal symptoms in patients with early breast cancer. *Eur J Cancer* 2005; 41: 708–714
- 40 Mariani L *et al.* Hot-flashes in breast cancer survivors: effectiveness of low-dosage fluoxetine. A pilot study. *J Exp Clin Cancer Res* 2005; 24: 373–378
- 41 Nikander E *et al.* Effects of phytoestrogens on bone turnover in postmenopausal women with a history of breast cancer. *J Clin Endocrinol Metab* 2004; 89: 1207–1212
- 42 Pandya KJ *et al.* Gabapentin for hot flashes in 420 women with breast cancer: a randomised double-blind placebo-controlled trial. *Lancet* 2005; 366: 818–824
- 43 Pandya KJ *et al.* Oral clonidine in postmenopausal patients with breast cancer experiencing tamoxifen-induced hot flashes: a University of Rochester Cancer Center Community Clinical Oncology Program study. *Ann Intern Med* 2000; 132: 788–793
- 44 Pandya KJ *et al.* Pilot study using gabapentin for tamoxifen-induced hot flashes in women with breast cancer. *Breast Cancer Res Treat* 2004; 83: 87–89
- 45 Quella SK *et al.* Evaluation of soy phytoestrogens for the treatment of hot flashes in breast cancer survivors: A North Central Cancer Treatment Group Trial. *J Clin Oncol* 2000; 18: 1068–1074
- 46 Quella SK *et al.* Long term use of megestrol acetate by cancer survivors for the treatment of hot flashes. *Cancer* 1998; 82: 1784–1788
- 47 Rada G *et al.* Non-hormonal interventions for hot flushes in women with a history of breast cancer. *Cochrane Database Syst Rev* 2010; 9: CD004923
- 48 Stearns V *et al.* A pilot trial assessing the efficacy of paroxetine hydrochloride (Paxil) in controlling hot flashes in breast cancer survivors. *Ann Oncol* 2000; 11: 17–22
- 49 Stearns V *et al.* Paroxetine is an effective treatment for hot flashes: results from a prospective randomized clinical trial. *J Clin Oncol* 2005; 23: 6919–6930
- 50 Thompson EA *et al.* A pilot, randomized, double-blinded, placebo-controlled trial of individualized homeopathy for symptoms of estrogen withdrawal in breast-cancer survivors. *J Altern Complement Med* 2005; 11: 13–20
- 51 Thompson S *et al.* Levetiracetam for the treatment of hot flashes: a phase II study. *Support Care Cancer* 2008; 16: 75–82
- 52 Van Patten CL *et al.* Effect of soy phytoestrogens on hot flashes in postmenopausal women with breast cancer: a randomized, controlled clinical trial. *J Clin Oncol* 2002; 20: 1449–1455
- 53 Walker EM *et al.* Acupuncture versus venlafaxine for the management of vasomotor symptoms in patients with hormone receptor-positive breast cancer: a randomized controlled trial. *J Clin Oncol* 2010; 28: 634–640
- 54 Weitzner MA *et al.* A pilot trial of paroxetine for the treatment of hot flashes and associated symptoms in women with breast cancer. *J Pain Symptom Manage* 2002; 23: 337–345
- 55 Wu MF *et al.* The efficacy of sertraline for controlling hot flashes in women with or at high risk of developing breast cancer. *Breast Cancer Res Treat* 2009; 118: 369–375
- 56 Riechelmann RP *et al.* Drug interactions in oncology: how common are they? *Ann Oncol* 2009; 20: 1907–1912
- 57 Haddad A *et al.* The pharmacological importance of cytochrome CYP3A4 in palliation of symptoms: review and recommendations for avoiding adverse drug interactions. *Support Care Cancer* 2007; 15: 251–257
- 58 Desmarais JE *et al.* Interactions between tamoxifen and antidepressants via cytochrome P450 2D6. *J Clin Psychiatry* 2009; 70: 1688–1697

Deutschsprachige Zusatzinformationen online abrufbar unter:
www.thieme-connect.de/ejournals/toc/gebfra.